Tenofovir/FTC/elvitegravir/cobicistat is the first single-tablet antiretroviral regimen that includes an HIV integrase inhibitor rather than targeting reverse transcriptase alone.
The U.S. Department of Health and Human Services (DHHS) now recommends the single-tablet regimen tenofovir/FTC/elvitegravir/cobicistat (Stribild) as an alternative treatment for antiretroviral-naive HIV-infected patients with estimated creatinine clearance >70 mL/minute/1.73 m2. The new tablet was recently approved by the FDA for use in antiretroviral-naive HIV-infected patients based on the results of two randomized trials. In both of those trials, the combination tablet was noninferior to a DHHS-preferred treatment regimen (tenofovir/FTC/efavirenz [Atripla] or tenofovir/FTC + ritonavir-boosted atazanavir) and was generally well tolerated (JW AIDS Clin Care Jul 9 2012).
The new single-tablet regimen is the first “one pill, once daily” table…
Reviewing Author
DisclosuresConsultant / Advisory boardGilead Sciences; ViiV; Merck
RoyaltiesUpToDate, Inc.
Grant / Research supportNIH; Department of Health and Human Services
DisclosuresConsultant / Advisory boardGilead Sciences; ViiV; Merck
RoyaltiesUpToDate, Inc.
Grant / Research supportNIH; Department of Health and Human Services